SMN2 and proximal spinal muscular atrophy: The FDA authorized risdiplam (Evrysdi), a modifier of SMN2 splicing [82], as the first oral medication to treat SMA in 2020, and the EMA approved it in March 2021 for children older than 2 months [83] (Figure 4 and Table 2).